Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC

被引：0
|
作者：
Pinto, L. Masfarre [1 ]
Rocha, P. [2 ]
Clave, S. [3 ]
Gorro, N. Navarro [4 ]
Sanchez, I. [3 ]
Giner, M. [5 ]
Lloret, A. Corbera [4 ]
Garcia, A. Taus [4 ]
Parreira, A. S. D. F. M. [6 ]
Paricio, B. Bellosillo [7 ]
Arriola, E. [1 ]
机构：
[1] Hosp Mar Parc Salut Mar, Dept Oncol, Barcelona, Spain
[2] Hosp Mar Parc Salut Mar, Translat Mol Pathol Dept, Barcelona, Spain
[3] Hosp Mar Parc Salut Mar, Dept Pathol, Barcelona, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Hosp Mar Parc Salut Mar, Barcelona, Spain
[6] Hosp Univ Son Espases, Med Oncol, Palma De Mallorca, Spain
[7] Hosp Mar Parc Salut Mar, Dept Mol Biol, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
193P
引用
收藏
页码：S145 / S146
页数：2
相关论文
共 50 条
  • [31] KRAS (G12C) mediated mRNA translation program
    Singh, Kamini
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [32] Covalent Guanosine Mimetic Inhibitors of G12C KRAS
    Xiong, Yuan
    Lu, Jia
    Hunter, John
    Li, Lianbo
    Scott, David
    Choi, Hwan Geun
    Lim, Sang Min
    Manandhar, Anuj
    Gondi, Sudershan
    Sim, Taebo
    Westover, Kenneth D.
    Gray, Nathanael S.
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 61 - 66
  • [33] The emerging target KRAS G12C in genitourinary malignancies
    Grivas, Petros
    Necchi, Andrea
    Bratslavsky, Gennady
    Shapiro, Oleg
    Jacob, Joseph
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Killian, Keith
    Williams, Erik
    Ramkissoon, Shakti H.
    Severson, Eric Allan
    Hemmerich, Amanda
    Schrock, Alexa Betzig
    Chung, Jon
    McGregor, Kimberly
    Reddy, Prasanth
    Alexander, Brian Michael
    Sokol, Ethan
    Danziger, Natalie
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Two new agents target KRAS G12C
    Diana Romero
    Nature Reviews Clinical Oncology, 2020, 17 (1) : 6 - 6
  • [35] Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
    Woodcock, M.
    Tsai, Y. S.
    Azam, S. H.
    Thorne, L. B.
    Kanchi, K. L.
    Parker, J. S.
    Vincent, B. G.
    Pecot, C. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S599 - S600
  • [36] LANDSCAPE OF KRAS G12C MUTATIONS IN GENITOURINARY MALIGNANCIES
    Rebecca, Sager A.
    Michael, Basin F.
    Hanan, Goldberg
    Jeffrey, Ross S.
    Gennady, Bratslavsky
    Joseph, Jacob M.
    Petros, Grivas
    Andrea, Necchi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S69 - S69
  • [37] Two new agents target KRAS G12C
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (01) : 6 - 6
  • [38] Targeting KRAS G12C mutation in lung adenocarcinoma
    Rohatgi, Anjali
    Govindan, Ramaswamy
    LUNG CANCER, 2022, 165 : 28 - 33
  • [39] Targeting KRAS G12C mutations in colorectal cancer
    Zhao, Ming-He
    Wu, Ai-Wen
    GASTROENTEROLOGY REPORT, 2023, 11
  • [40] KRAS G12C inhibition and innate immune targeting
    Tani, Tetsuo
    Kitajima, Shunsuke
    Conway, Ella B.
    Knelson, Erik H.
    Barbie, David A.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (03) : 167 - 174
12345